



Deciphera Pharmaceuticals, Inc. to Participate in Citi's 13th Annual Biotech Conference

August 29, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 29, 2018-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will participate in a panel discussion on targeted therapies in oncology at Citi's 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 3:15 PM ET at the Four Seasons Hotel Boston.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/news-events/events-presentations>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a "switched off" or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-

targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180829005096/en/>

Source: Deciphera Pharmaceuticals, Inc.

Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com

or

Investor Relations:

Argot Partners

Laura Perry, 212-600-1902

Laura@argotpartners.com

or

Sam Martin, 212-600-1902

Sam@argotpartners.com

or

Company:

Deciphera Pharmaceuticals, Inc.

Christopher J. Morl, 781-209-6418

Chief Business Officer

cmorl@deciphera.com